Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared David Planchard’s, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy post on X, adding:
“Important study tackling a highly relevant question in EGFRm NSCLC.
One observation: the PFS and OS curves look visually identical, even though the reported medians differ – perhaps suggesting an inadvertent duplication of the PFS KM figure. But, if these represent PFS (based on medians/CIs), the shape of the curve appears somewhat atypical for a randomized trial with scheduled assessments.”
Quoting David Planchard’s post:
“FLAURA2 regimen raises the bar! New data from a China study shows impressive PFS/OS gains for Osi + Chemo in EGFRm + TP53 co-mutated pts. Confirms 1L SOC status across the board: TP53 mut, WT, and Asian subgroups…
Finding a better future strategy won’t be easy.”
Other articles featuring Biagio Ricciuti and David Planchard on OncoDaily.
